跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,459 条关于
“CheckMate 9ER”
全部
2,459
临床试验
1,920
药物
226
机构
37
资讯
276
去年
CheckMate-9ER: Glycoproteomic Analysis Identifies Potential Biomarkers for Nivolumab Plus Cabozantinib in Advanced RCC
2年前
Cabozantinib/Nivolumab Shows Consistent Benefits in RCC, Except for Favorable-Risk Group
去年
IO/TKI Doublets Show Consistent Efficacy in Metastatic Clear Cell Renal Cell Carcinoma
去年
Advancements in Renal Cell Carcinoma Treatment: Immunotherapy Combinations and Personalized Approaches
去年
Machine Learning Model Outperforms Individual Biomarkers in Predicting Advanced Renal Cell Carcinoma Treatment Response
去年
Lenvatinib-Pembrolizumab Combination Shows Promise as First-Line Treatment for Advanced Renal Cell Carcinoma
去年
Glycoproteomic Analysis Identifies Potential Biomarkers for Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
2年前
Cabozantinib Plus Nivolumab Emerges as Preferred First-Line Treatment for Advanced Renal Cell Carcinoma
去年
CheckMate 901: Nivolumab Plus Chemotherapy Improves Survival in Advanced Urothelial Carcinoma
2年前
Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC
第 1 页,共 28 页
上一页
下一页